Skip to Content

A clinical trial of recombinant angiotensin II infusion in catecholamine-resistant hypotension

Site-PI: Raghavan Murugan, MD

Funding: La Jolla Pharmaceutical

Catecholamine-resistant hypotension is an often a fatal condition resulting from an underlying cause such as septic shock, trauma, or severe drug reactions. Approximately, 6-7% of patients will require excessive doses of vasopressors and will be deemed to be resistant. Angiotensin II is a hormone produced by the renin angiotensin aldosterone system that modifies blood pressure via regulation of vascular smooth muscle tone and extracellular fluid homeostasis.  As a site investigator of this phase 3, placebo-controlled, randomized, double-blind, multi-center study, Dr. Murugan is investigating the role of angiotensin II infusion in patients with catecholamine-resistant hypotension.